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Abstract Chronic progressive external ophthalmoplegia
(CPEO) is a relatively common mitochondrial disorder.
Weakness of the extra-ocular, limb girdle and laryngeal
muscles are established clinical features. Respiratory
muscle involvement however has never been studied sys-
tematically, even though respiratory complications are one
of the main causes of death. We therefore determined the
prevalence and nature of respiratory muscle involvement in
23 patients with genetically conﬁrmed CPEO. The main
ﬁnding was decreased respiratory muscle strength, both
expiratory (76.8% of predicted, p = 0.002) and inspiratory
(79.5% of predicted, p = 0.004). Although the inspiratory
vital capacity (92.5% of predicted, p = 0.021) and the
forced expiratory volume in 1 s (89.3% of predicted,
p = 0.002) were below predicted values, both were still
within the normal range in the majority of patients. Expi-
ratory weakness was associated with a decreased vital
capacity (q = 0.502, p = 0.015) and decreased peak
expiratory ﬂow (q = 0.422, p = 0.045). Moreover,
expiratory muscle strength was lower in patients with
limb girdle weakness (62.6 ± 26.1% of predicted vs.
98.9 ± 22.5% in patients with normal limb girdle strength,
p = 0.003), but was not associated with other clinical
features, subjective respiratory complaints, disease severity
or disease duration. Since respiratory involvement in
CPEO is associated with severe morbidity and mortality,
the present data justify periodic assessment of respiratory
functions in all CPEO patients.
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Introduction
Chronic progressive external ophthalmoplegia (CPEO) is
one of the most common mitochondrial disorders in adults
[1]. The characteristic clinical feature is a slowly pro-
gressive weakness of the extraocular muscles, resulting in
ptosis and restriction of eye movements [5]. CPEO is
however often a multi-system disorder, affecting the limb
girdle and laryngeal muscles, retina, cochlea, cerebrum,
cerebellum or heart. The prevalence and nature of respi-
ratory involvement have never been systematically studied.
Two cohort studies have shown that respiratory com-
plications are one of the main causes of death in CPEO [2,
12]. Conversely, studies that speciﬁcally investigated
respiratory function in CPEO are limited to case reports
and studies on small series of patients without a genetically
conﬁrmed diagnosis [3, 7, 8, 11, 15, 19]. Most consistent
ﬁndings were a decreased ventilatory drive to hypoxia and
hypercapnia and respiratory muscle weakness. However,
the prevalence, nature and determinants of respiratory
involvement in CPEO cannot be reliably determined from
these uncontrolled studies. More insight into the nature of
respiratory involvement is nevertheless desirable, since it
may help to prevent respiratory complications and respi-
ration-related deaths [12].
In a large cohort of genetically conﬁrmed CPEO
patients, we performed an extensive standardized
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rometry, measurement of respiratory muscle strength and
of diffusion capacity. In order to identify possible deter-
minants of respiratory muscle involvement, patients also
completed questionnaires on subjective respiratory symp-
toms and underwent a standardized neurological
examination.
Methods
Patients
All CPEO patients known in the Department of Neurology
of the Radboud University Nijmegen Medical Centre were
invited to participate. As there are no commonly accepted
criteria for CPEO, we only included patients with both
characteristic clinical features and a known causative
mutation. Consequently, all participants met the following
three criteria:
1. a phenotype including a slowly progressive bilateral
external ophthalmoplegia
2. a proven pathogenic mutation or deletion in the
mitochondrial DNA (mtDNA) or in the nuclear
polymerase gamma 1 (POLG1), Twinkle or adenine
nucleotide translocator 1 (ANT1) genes
3. exclusion of an alternative diagnosis.
These inclusion criteria also cover two more or less
speciﬁc mitochondrial phenotypes with external ophthal-
moplegia as a key symptom: the Kearns-Sayre syndrome
(KSS: external ophthalmoplegia, pigmented retinopathy,
age of onset below 20 years and at least one of the fol-
lowing symptoms: cardiac conduction block, cerebellar
ataxia, elevated CSF protein content) [14] and SANDO
(Sensoric Atactic Neuropathy, Dysarthria and Ophthalmo-
plegia) [4, 9]. In this article, we use the term CPEO to
describe all patients meeting the inclusion criteria, and the
terms KSS and SANDO to describe the speciﬁc phenotypes
only.
All participants gave informed consent. The local ethics
committee approved this study, and the patients’ consent
was obtained according to the Declaration of Helsinki.
Methods
Patients’ characteristics
We performed a standardized neurological examination,
including an assessment of muscle strength (ocular, bulbar
and extremities), sensory functions, tendon reﬂexes and
coordination. We also measured the length, and weight and
calculated the body mass index. Results of ancillary
investigations and of genetic investigations were derived
from the patients’ ﬁles.
Subjective complaints
All participants completed a questionnaire with items on
history of smoking and pulmonary disease, dyspnea,
swallowing, coughing and quality of sleep. We assessed the
level of independence in daily activities using the modiﬁed
Rankin score (mRS), with an mRS B2 indicating inde-
pendence [23].
Pulmonary function tests
All eligible patients were invited to undergo respiratory
function tests in our pulmonary function department. To
exclude a possible selection bias (patients who were unable
to visit our hospital might have more advanced disease),
we offered to perform respiratory function tests at home for
those patients who were willing to participate but could not
visit our hospital.
Respiratory function tests were performed according the
American Thoracic Society/European Respiratory Society
standards [17]. First, we measured respiratory muscle
strength, including the maximal expiratory mouth pressure
(PE-Max), and the maximal inspiratory mouth pressure
(PI-Max). Next, to evaluate the effect of respiratory muscle
weakness on the inspiratory vital capacity (IVC), we per-
formed spirometry, including the forced expiratory volume
in 1 s (FEV1), the FEV1/IVC ratio, the peak expiratory
ﬂow (PEF) and the forced inspiratory volume in 1 s
(FIV1). We also measured the total lung capacity (TLC),
the diffusion capacity for carbon monoxide (TLCO) and
the diffusion capacity for carbon monoxide corrected for
alveolar volume (KCO).
All tests were performed by a trained pulmonary func-
tion technician. The TLC, FIV1, TLCO and KCO could not
be measured at the patients’ homes and were therefore
measured in patients visiting our hospital only.
Statistical analysis
Data analysis was performed using SPSS (version 17.0). To
assess the extent of pulmonary involvement in CPEO we
compared the test results of the individual participants to
their own predicted values using a paired Wilcoxon signed
ranks test. For comparison between various subgroups, we
performed an independent Mann-Whitney U test on the test
results relative to the predicted values, which are noted as
‘‘value % pred’’: for example, ‘‘IVC’’ indicates the inspi-
ratory vital capacity (in liters), whereas ‘‘IVC% pred’’
indicates the inspiratory vital capacity relative to the pre-
dicted value (in %). A Fisher’s exact test was used to
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late correlations. The signiﬁcance level was set at p\0.05
(two-tailed) in all cases.
Results
Patients’ characteristics
We identiﬁed 26 eligible patients. All were invited to
participate; two patients refused (one male patient with an
m.12315G[A mutation and one female patient with a
mtDNA deletion). In general, their clinical features and
disease severity were in the same range as the participants.
During the tests, one of the participants appeared to be
unable to follow the instructions because of severe vision
and hearing impairments. Her test results were unreliable
and therefore excluded from all analyses. Of the remaining
23 patients (11 female, 12 male), 14 (60.9%) were tested in
the pulmonary function department and 9 (39.1%) at home.
Mean age of the participants was 49.1 ± 11.0 years, and
mean age at onset was 22.9 ± 12.2 years (Table 1).
Mutation type included a single mtDNA deletion in 14
patients (60.9%), a mtDNA point mutation in 4 (17.4%)
a n daP O L G 1m u t a t i o ni n5( 2 1.7%). POLG1 mutations
included compound heterozygous T251I, P587L and
A957S mutations in one patient (patient 19), a homozy-
gous A467T in two patients (patients 20 and 21), and
compound heterozygous A467T and W748S mutations in
two (patients 22 and 23). Three patients (19, 20 and 23)
also had multiple mtDNA deletions in their skeletal
muscle mtDNA. None of the patients had Twinkle or
ANT1 mutations. One patient (with a mtDNA deletion)
met the criteria for KSS [14] and four (all with POLG1
mutations) for SANDO. Fifteen patients (65.2%) were
independent in daily life activities, whereas eight (34.7%)
were not.
Questionnaires
Five patients (21.7%) were current smokers, and 6 of the
remaining 18 patients (33.3%) were former smokers
Table 1 Demographical, genetic and clinical results of 23 CPEO patients
No. Sex/age/age
at onset
Mutation Smoking
history
Pulmon.
history
CNS
involv.
Limb
girdle
Periph.
neurop.
Dysarthria/
dysphagia
Other
1 F/28/21 Deletion C – – – – -/-
2 F/43/32 Deletion – – – – – -/- PHL, HT
3 F/29/17 Deletion C P – ? – -/?
4 F/35/14 Deletion – – M – – -/-
5 M/32/8 Deletion – – CA, CI ? – -/? PHL, RI
6 F/52/25 Deletion – – – ? – -/-
7 F/62/34 Deletion F – CA, CI, E ? – -/- CM
8 F/43/15 Deletion C – – ? – ?/?
9 M/54/25 Deletion F – – ? – ?/?
10 M/40/11 Deletion C – – – – -/-
11 M/45/14 Deletion F – CA, CI ? – ?/? CB, PHL, RI
12 F/54/13 Deletion F – – ? – -/-
13 F/61/17 Deletion F – – – – -/-
14 M/63/12 Deletion – P – ? – ?/?
15 M/55/48 m.4267A[G– – – ? – -/-
16 M/66/36 m.12315G[A– – – – – -/-
17 F/54/12 m.3243A[G F A, P CA, M ? – ?/- PHL, RI, DM
18 M/57/12 m.3243A[GC A C I – ?- /- PHL, DM
19 M/63/53 POLG1 – – – – ?- /-
20 M/52/39 POLG1 – – CA, CI ? SAN ?/- PHL, RI
21 M/43/23 POLG1 – – CA, CI ? SAN ?/? PHL, RI
22 F/51/24 POLG1 – A, P CA ? SAN ?/? PHL
23 M/48/21 POLG1 – – CA, CI – SAN ?/? PHL, RI
CNS central nervous system, POLG1 polymerase gamma 1, C current smoker, F former smoker, P pneumonia, A asthma, M migraine,
CA cerebellar ataxia, CI cognitive impairment, E epilepsy, SAN sensoric atactic neuropathy, CM cardiomyopathy, CB cardiac conduction block,
PHL peripheral hearing loss, RI retinal involvement, DM diabetes mellitus, HT hypothyroidism
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123(Table 1). Three patients reported a history of asthma, of
whom only one used pulmonary medication (budesonide).
Three patients (13.0%) had a history of pneumonia,
including two out of the three patients with asthma. Shortly
after participating in this study, one additional patient
(no. 3) developed severe pneumonia, requiring mechanical
ventilation and long-term rehabilitation. We included this
patient in the further analyses on patients with a history of
pneumonia. Fourteen patients (60.9%) reported exertional
dyspnea. Three patients (13.0%), two current smokers and
one patient with asthma, reported dyspnea at rest. Eleven
patients (47.8%) reported dysphagia, of whom three
(13.0%) also reported difﬁculty coughing.
Pulmonary function tests
The main ﬁnding was decreased expiratory and inspiratory
muscle strength: PE-Max was 76.8% of the predicted value
(p = 0.002) and PI-max 79.5% (p = 0.004) (Table 2).
Lower PE-Max% pred was associated with lower PI-Max%
pred (q = 0.625, p = 0.001) but also with lower IVC%
pred (q = 0.502, p = 0.015) and lower PEF% pred
(q = 0.422, p = 0.045). IVC was also signiﬁcantly
decreased (92.5% of predicted, p = 0.021), as were FEV1
(89.3% of predicted, p = 0.003) and TLCO (81.9% of
predicted, p = 0.002). The decreased TLCO is unlikely
due to intrinsic lung disease, since the diffusion capacity
Table 2 Results of respiratory function assessment
No. BMI PE-Max PI-Max IVC TLC FEV1 FEV1/IVC PEF FIV1 TLCO KCO
1 24.7 9.4 (101) 8.0 (109) 3.8 (100) 4.7 (91) 3.3 (101) 87 9.0 (125) 3.3 (94) 8.9 (94) 2.0 (109)
2 34.7 11.6 (118) 8.3 (104) 4.7 (121) 6.2 (108) 3.7 (115) 80 8.0 (110) 4.5 (128) 8.2 (86) 1.4 (87)
3 16.8 4.0 (45) 5.1 (74) 2.1 (61) 4.3 (89) 2.0 (68) 95 5.2 (76) 2.0 (60) 6.9 (77) 1.8 (94)
4 23.5 9.5 (95) 6.6 (79) 3.8 (90) 5.1 (83) 3.3 (92) 87 8.0 (103) 3.7 (93) 7.0 (68) 1.6 (94)
5 17.9 7.7 (52) 7.2 (67) 4.0 (92) 4.9 (84) 3.1 (87) 78 7.8 (89) 3.8 (94) 7.2 (73) 1.5 (90)
6 34.4 4.3 (46) 5.4 (73) 2.5 (77) 2.1 (79) 85 5.6 (85)
7 30.0 7.3 (74) 5.4 (66) 3.9 (111) 6.9 (116) 2.6 (87) 67 8.3 (121) 3.8 (118) 7.8 (89) 1.3 (86)
8 19.0 2.8 (30) 3.7 (50) 2.9 (84) 4.5 (86) 2.6 (90) 95 6.2 (91) 2.4 (77) 6.5 (74) 1.6 (95)
9 27.8 2.4 (19) 1.7 (20) 4.4 (86) 3.5 (91) 81 6.8 (74)
10 27.3 10.7 (75) 4.4 (44) 4.8 (82) 6.1 (75) 3.7 (81) 77 10.0 (99) 4.3 (81) 10.0 (80) 1.7 (112)
11 18.9 6.9 (51) 10.2 (109) 4.8 (100) 3.8 (103) 81 9.0 (100)
12 21.8 5.1 (52) 5.0 (63) 3.7 (105) 5.3 (94) 2.9 (98) 77 6.8 (100) 3.6 (113) 7.3 (74) 1.5 (97)
13 30.1 10.6 (116) 8.0 (112) 3.2 (109) 4.4 (89) 2.3 (97) 78 7.1 (117) 2.9 (112) 5.6 (73) 1.4 (89)
14 25.9 7.2 (60) 2.7 (35) 3.7 (79) 2.7 (76) 72 5.5 (64)
15 25.3 12.7 (99) 8.2 (97) 5.1 (120) 6.8 (103) 4.5 (135) 87 11.9 (142) 5.0 (130) 9.5 (101) 1.5 (104)
16 24.2 10.1 (86) 5.0 (68) 2.8 (80) 2.3 (84) 80 7.6 (103)
17 23.0 7.7 (80) 8.1 (105) 3.8 (109) 5.3 (95) 2.3 (80) 61 5.6 (83) 3.4 (111) 7.6 (79) 1.5 (97)
18 16.9 8.4 (66) 8.2 (99) 3.5 (72) 2.6 (70) 75 6.2 (70)
19 29.1 16.5 (138) 8.2 (110) 3.7 (92) 6.4 (97) 2.1 (68) 56 5.9 (75) 3.5 (98) 9.4 (107) 1.8 (132)
20 24.4 9.0 (69) 8.0 (91) 3.6 (81) 2.8 (81) 80 8.1 (94)
21 18.0 12.3 (89) 6.4 (67) 5.3 (94) 7.9 (99) 4.1 (94) 78 9.7 (99) 5.1 (98) 8.6 (71) 1.3 (83)
22 21.5 10.7 (111) 8.9 (116) 3.5 (101) 2.6 (90) 74 5.6 (83)
23 27.2 12.7 (95) 6.6 (73) 4.4 (82) 3.6 (87) 82 9.1 (95)
Mean 8.68 6.49 3.82 5.63 2.97 79 7.52 3.66 7.89 1.56
SD 3.49 2.13 0.80 1.11 0.70 9.2 1.73 0.88 1.27 0.20
%pred. 76.8** 79.5** 92.5* 93.6 89.3** 99.5 95.6 100.5 81.9** 97.9
In value (percentage of predicted). Blank ﬁelds indicate that the patient was tested at home and as a result the speciﬁc test was not performed
BMI body mass index (in kg/m
2), PE-Max maximal expiratory mouth pressure (in kPa), PI-Max maximal inspiratory mouth pressure (in kPa),
IVC inspiratory vital capacity (in liters), TLC total lung capacity (in liters), FEV1 forced expiratory volume in 1 s (in liters), PEF peak expiratory
ﬂow (in liters/s), FIV1 forced inspiratory volume in 1 s (in liters), TLCO diffusion capacity for carbon monoxide (in mmol/min/kPa),
KCO diffusion capacity for carbon monoxide corrected for alveolar volume (mmol/min/kPa/liter)
* Paired Wilcoxon p\0.05
** Paired Wilcoxon p\0.01
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123corrected for alveolar volume (i.e., the KCO) was normal
(97.9% of predicted, p = 0.26). Three patients had
obstructive pulmonary disease (FEV1/IVC \70%), of
whom two were former smokers and one a nonsmoker
without a history of pulmonary disease. In these three
patients, all other test results were within the same range as
the rest of the cohort.
Determinants of respiratory function
Patients with limb girdle weakness had a lower PE-Max%
pred than patients with normal limb girdle strength
(62.6 ± 26.1 vs. 98.9 ± 22.5%, p = 0.005). Limb girdle
weakness was not associated with any of the other
outcomes. PEF% pred was lower in patients who reported
difﬁculty coughing (74.3 ± 9.5 vs. 98.8 ± 18.1%,
p = 0.028), as well as in patients with a history of pneu-
monia (76.6 ± 9.0 vs. 99.7 vs. 18.3%, p = 0.019). None of
the other subjective complaints, demographic or clinical
features were associated with any of the respiratory test
results.
As to a possible genotype-phenotype relation, there were
no differences in any of the respiratory test results between
patients with mtDNA mutations or deletions and patients
with POLG1 mutations, though there was a strong ten-
dency toward a lower PE-Max% pred in patients with
mtDNA deletions (66.4 ± 31.0 vs. 100.5 ± 26.0%,
p = 0.064). In addition, all eight patients with a PE-Max
below 65% of the predicted value had a mtDNA deletion.
Discussion
We found that both expiratory and inspiratory muscle
strength was decreased in CPEO patients and that
decreased respiratory muscle strength resulted in a
decreased vital capacity, FEV1 and PEF. Respiratory
muscle weakness was associated with limb girdle weak-
ness, which is in concordance with studies in other myo-
pathies [21, 22]. In contrast, there was no association
between respiratory muscle function and other clinical
features, disease duration, disease severity, subjective
respiratory complaints or mutation type.
In the present study, we took several measures to
include a representative cohort: our study was prospective
and used strict clinical and genetic inclusion criteria. We
also offered to perform the tests at the patients’ homes,
which resulted in a high participation rate. This not only
enabled us to provide a representative overview of the
prevalence and nature of respiratory involvement in CPEO,
but also to identify possible determinants of respiratory
involvement. The present results therefore not only conﬁrm
but also extend the conclusions of the previous smaller case
studies on respiratory involvement in CPEO [3, 7, 15].
A major consequence of decreased respiratory muscle
weakness in neuromuscular disorders is an increased risk
of pneumonia [6]. CPEO patients may however be par-
ticularly prone to pneumonias because of concurrent lar-
yngeal muscle weakness. Laryngeal muscle weakness can
lead to aspiration of foods and to diminish glottic closure
during coughing [12, 13, 20]. Inadequate glottic closure in
turn, especially when combined with decreased inspira-
tory and expiratory strength, results in insufﬁcient gen-
eration of intrathoracic pressure and thus in impaired
expectoration.
In addition to an increased risk of pneumonia in CPEO,
the course of pneumonia may theoretically also be more
severe: a decreased ventilatory drive to hypoxia or hyper-
capnia predisposes to respiratory failure and prolonged
weaning after mechanical ventilation [3, 7, 19]. In addition,
CPEO patients may have trouble meeting the increased
demands associated with infections because of limited
metabolic and hemodynamic reserves [16].
Despite the fact that pneumonia is one of the main
causes of death in CPEO, little is known about its pre-
vention [2, 12]. As in other neuromuscular disorders,
conservative treatment aimed at minimizing the risk of
pneumonia seems rational [18]. This includes speech
therapy and physiotherapy aimed at optimizing cough
effectiveness and swallowing function, while a cricopha-
ryngeal myotomy may be performed in selected cases of
severe dysphagia [13]. Moreover, any sign of pneumonia
or respiratory failure in a CPEO patient should prompt
rapid diagnosis and treatment to prevent further
complications.
The present study does not quantify the relative con-
tributions of neurogenic or myogenic weakness of the
respiratory muscles, nor the relative contribution of the
various muscles involved in respiration. For instance we
did not directly measure diaphragm strength, which
ideally requires transdiaphragmic esophageal and gastric
manometry. This is however an invasive procedure and
carries a risk of aspiration. Alternative indicators for
diaphragm strength are the nasal sniff pressure and the
supine vital capacity. The use of supine vital capacity is
however limited by the lack of normal values. Sniff
pressure is mainly validated in amyotrophic lateral
sclerosis and depends partly on the nasal airway con-
ductance, while in patients with myopathies, PI-Max is
possibly a more reliable indicator of inspiratory weak-
ness than nasal pressure [24]. Therefore, in this study we
used the PI-Max as an indicator of diaphragm strength,
since it is also correlated to transdiaphragmic pressure
[10].
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123Conclusions
Respiratory muscle weakness is common in CPEO
patients. The presence of respiratory muscle weakness has
important consequences for patient management, since it is
associated with an increased risk of pneumonia and pos-
sibly of increased mortality. As there are no clinical pre-
dictors of respiratory muscle weakness and the rate of
progression of respiratory muscle weakness has yet to be
determined in a longitudinal study, we propose that peri-
odic assessment of pulmonary function tests including
respiratory muscle strength measurements should be
included in evaluation of CPEO patients.
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